Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Investor Day Review
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 7
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 7
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.
Needham analyst says, "Optimer management hosted an investor meeting in NYC yesterday. Management outlined plans for Dificid expansion beyond the hospital setting to long-term care facilities, reviewed data presented at recent medical conferences, and explained the basis of its pharmacoeconomic analysis. Roy Chemaly of the MD Anderson CC highlighted challenges associated with C. difficile (CDI) in oncology...We reiterate our rating. Although it is early in the Dificid launch, we are generally encouraged by progress to date and continue to expect benefits of the drug over vancomycin to gradually gain recognition in the commercial setting. We believe the stock is undervalued (~$430M EV)."
"Our 2011 and 2012 EPS estimates are unchanged at $(0.64) and $(0.10). Optimer ended 3Q11 with $129M in cash. We expect Optimer to end the year with ~$100M in cash."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.10 yesterday.
Needham analyst says, "Optimer management hosted an investor meeting in NYC yesterday. Management outlined plans for Dificid expansion beyond the hospital setting to long-term care facilities, reviewed data presented at recent medical conferences, and explained the basis of its pharmacoeconomic analysis. Roy Chemaly of the MD Anderson CC highlighted challenges associated with C. difficile (CDI) in oncology...We reiterate our rating. Although it is early in the Dificid launch, we are generally encouraged by progress to date and continue to expect benefits of the drug over vancomycin to gradually gain recognition in the commercial setting. We believe the stock is undervalued (~$430M EV)."
"Our 2011 and 2012 EPS estimates are unchanged at $(0.64) and $(0.10). Optimer ended 3Q11 with $129M in cash. We expect Optimer to end the year with ~$100M in cash."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
- Jefferies Downgrades BSE Limited (BSE:IN) to Underperform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
